We are live on ! Find out more
RHJA

Rice Hall James & Associates Portfolio holdings

AUM $2.05B
1-Year Est. Return 43.16%
This Fund
S&P 500
This Quarter Est. Return
+7.57%
1 Year Est. Return
+43.16%
3 Year Est. Return
+139.79%
5 Year Est. Return
+169.96%
10 Year Est. Return
+906.29%
AUM
$1.74B
AUM Growth
+$18.9M
Cap. Flow
-$61.5M
Cap. Flow %
-3.53%
Top 10 Hldgs %
23.9%
Holding
276
New
11
Increased
44
Reduced
193
Closed
16

Top Buys

Rank Stock Value
1
OABI icon
OmniAb
OABI
+$13M
2
DOCS icon
Doximity
DOCS
+$10.2M
3
LOB icon
Live Oak Bancshares
LOB
+$7.32M
4
RXO icon
RXO
RXO
+$7.31M
5
ACAD icon
Acadia Pharmaceuticals
ACAD
+$6.78M

Top Sells

Rank Stock Value
1
AERI
Aerie Pharmaceuticals
AERI
+$24.3M
2
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$12.4M
3
LGND icon
Ligand Pharmaceuticals
LGND
+$12.3M
4
XPO icon
XPO
XPO
+$7.84M
5
RXT icon
Rackspace Technology
RXT
+$5.42M

Sector Composition

Rank Sector Weight
1 Technology 27.01%
2 Healthcare 26.13%
3 Industrials 15.45%
4 Consumer Discretionary 11.41%
5 Communication Services 6.32%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SRRK icon
251
Scholar Rock
SRRK
$6.32B
$405K 0.02%
44,723
-2,258
-5% -$18.1K
WMT icon
252
Walmart Inc
WMT
$897B
$382K 0.02%
8,073
– –
AAPL icon
253
Apple
AAPL
$4.5T
$364K 0.02%
2,800
-3,300
-54% -$472K
MCO icon
254
Moody's
MCO
$82.8B
$351K 0.02%
1,260
-580
-32% -$159K
PG icon
255
Procter & Gamble
PG
$340B
$312K 0.02%
2,059
– –
JPM icon
256
JPMorgan Chase
JPM
$956B
$276K 0.02%
2,058
– –
SBUX icon
257
Starbucks
SBUX
$119B
$247K 0.01%
2,490
– –
WDFC icon
258
WD-40
WDFC
$3.15B
$234K 0.01%
1,450
– –
MSFT icon
259
Microsoft
MSFT
$3.76T
$226K 0.01%
944
– –
MRSH
260
Marsh
MRSH
$91B
$223K 0.01%
1,350
– –
AMZN icon
261
Amazon
AMZN
$3T
– –
-2,120
Closed -$240K
BMY icon
262
Bristol-Myers Squibb
BMY
$132B
– –
-3,370
Closed -$240K
BVS icon
263
Bioventus
BVS
$1.17B
– –
-533,322
Closed -$3.73M
CCRD
264
DELISTED
CoreCard
CCRD
– –
-108,318
Closed -$2.36M
CERT icon
265
Certara
CERT
$1.23B
– –
-113,015
Closed -$1.5M
CLAR icon
266
Clarus
CLAR
$145M
– –
-181,369
Closed -$2.44M
DLTH icon
267
Duluth Holdings
DLTH
$151M
– –
-314,137
Closed -$2.21M
EBS icon
268
Emergent Biosolutions
EBS
$229M
– –
-53,396
Closed -$1.12M
KPTI icon
269
Karyopharm Therapeutics
KPTI
$44.4M
– –
-60,606
Closed -$4.96M
LNTH icon
270
Lantheus
LNTH
$6.59B
– –
-61,607
Closed -$4.33M
PEP icon
271
PepsiCo
PEP
$188B
– –
-2,643
Closed -$431K
TNL icon
272
Travel + Leisure Co
TNL
$4.5B
– –
-58,400
Closed -$1.99M
INFN
273
DELISTED
Infinera Corporation Common Stock
INFN
– –
-21,749
Closed -$105K
NATI
274
DELISTED
National Instruments Corp
NATI
– –
-13,936
Closed -$526K
AERI
275
DELISTED
Aerie Pharmaceuticals
AERI
– –
-1,603,458
Closed -$24.3M
8 9 10
11
12

Similar funds

RC
RBF Capital San Francisco, California $2.05B AUM 29.64% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
IL
Investure LLC Charlottesville, Virginia $2.04B AUM 15.91% 1-Year Est. Return
BC
BIT Capital Berlin, Germany $2.07B AUM 157.17% 1-Year Est. Return
SAM
Southeastern Asset Management Memphis, Tennessee $2.03B AUM 7.06% 1-Year Est. Return
AG
Avala Global New York $2.08B AUM 87.66% 1-Year Est. Return
TA
TruWealth Advisors Metairie, Louisiana $2.08B AUM 21.15% 1-Year Est. Return
ACP
Avantyr Capital Partners New York $2.08B AUM

Rice Hall James & Associates's Q4 2022 Portfolio in Review

As of Q4 2022, Rice Hall James & Associates held 276 positions worth $1.74B, up 1.1% from $1.72B the previous quarter. Its ten largest holdings account for 24% of the portfolio.

Rice Hall James & Associates withdrew a net $61.5M in Q4 2022, closing 16 positions and reducing 193 holdings. Its most notable exit was Aerie Pharmaceuticals, an estimated $24.3M position sold in full.

By sector, the portfolio is most concentrated in Technology at 27% of assets, down from 27% a quarter earlier, followed by Healthcare and Industrials.

Against the trend, Rice Hall James & Associates opened a new position in OmniAb worth $8.94M.

  • Rice Hall James & Associates's largest Q4 2022 buy was OmniAb: 2,483,766 shares worth $8.94M.
  • Rice Hall James & Associates added most to Doximity in Q4 2022, an estimated $10.2M increase.
  • Rice Hall James & Associates's biggest Q4 2022 reduction was Ligand Pharmaceuticals, cutting an estimated $12.3M.
  • Rice Hall James & Associates fully exited Aerie Pharmaceuticals in Q4 2022, selling an estimated $24.3M.
  • Rice Hall James & Associates's ten largest holdings make up 24% of its $1.74B portfolio in Q4 2022.
  • Rice Hall James & Associates opened 11 new positions and closed 16 in Q4 2022.
  • Rice Hall James & Associates's portfolio value rose 1.1% quarter-over-quarter to $1.74B.

Based on Rice Hall James & Associates's 13F filing for Q4 2022, filed 27 Jan 2023.